 Page 1 of 17 Version date: 1. 4; 17 September  2018 PROTOCOL TITLE  
Validation of a point -of-care screening tool for children with sickle cell 
disease   
PRINCIPAL INVESTIGATOR : 
[CONTACT_492483]:   
TELEPHONE:  
EMAIL:   
SIGNATURE:  ________________________  
 Page 2 of 17 Version date: 1.4; [ADDRESS_1169711]  
Background:  Sickle cell disease (SCD) is the commonest genetic disorder in Nigeria , 
affecting up to 150,[ADDRESS_1169712] 6% of all childhood mortality and of those affected, 
only 10% in sub Saharan Africa (SSA) are likely to reach adolescence.  The clinical course 
of SCD is characterized by [CONTACT_841812], which may be severe, 
leading to significant morbidity and mortality . Timely diagnosis is key to pr event or 
manage these complications. However, current diagnostic methods rely  on laboratory 
systems that a re expensive and time consuming  or may even be unavailable.  
General Aim:  The primary study objective is to validate the HemeChip technology as a 
rapid , poin t-of care (POC) platform for screening  SCD.  
Methodology : This will be a  single site  cross -sectional  study . 
Expected Outcome : The validation of the HemeChip technology as an affordable, 
robust, easy -to-use POC  platform for screen ing of sickle cell disease ( SCD).   
 Page 3 of 17 Version date: 1.4; 17 September 2018  1.BACKGROUND
1.1 Introduction  
Sickle cell disease (SCD) is a group of inherited disorders of haemoglobin (Hb) 
synthesis, first described in the medical literature by [CONTACT_841813] 1910. Each year 
about 300,000 infants are born with SCD, including more than 200,000 cases in sub -
Sahar an Africa alone .1 In Nigeria, alone, there are over 150,000 of these children born 
annually and it is estimated that between 50 -90% of these children die before their 
fifth birthday .2 Overall , in the region , 6% of all childhood mortal ity in children less t han 
5 years of age is due to SCD complications  and infections . Vaso occlusive crisis and 
anemia are serious complications of SCD , with infection often being the major cause 
of hospi[INVESTIGATOR_602], crisis and death . 
SCD is caused by a point mutation in the six th codon of the beta glo bin chain that 
produces normal Hb  (HbA). This substitution of hydrophilic glutamic acid with 
hydrophobic valine produces sickle Hb  (HbS) , which is abnormally polymerized at low 
oxygen con ditions causing sickling. A bnormal polym eriza tion of HbS  affects red cell 
membrane properties, shape, and density, and subsequent critical changes in 
inflammatory cell and endothelial cell function .[ADDRESS_1169713] practi ces for diagnosing SCD are high performance liquid 
chromatography (HPLC) and bench -top Hb electrophoresis . These two approaches, 
however, require trained personnel and state -of-the-art facili ties, both of which may 
be lacking in many parts of sub -Saharan Africa  where the disease is most prevalent .[ADDRESS_1169714] patients.  
1.3  Relevance and Innovation  
HemeChip  diagnostic system offers an original and innovative solution, leveraging a 
novel en gineering approach, to point of care (POC)  diagnosis of SCD . HemeChip 
 Page 4 of 17 Version date: 1.4; 17 September 2018  separates h aemoglobin protein types in a miniscule volume of blood (1ŒºL) on a pi[INVESTIGATOR_841798] a micro -engineered chip with a controlled 
environment and electric field. Differences in Hb  mobilities allow separation to occur 
within the cellulose acetate paper. A micro -engineered design and multiple layer 
lamination approach  are utilized in fabrica ting the HemeChip. The design allows rapid 
manual assembly and results are available within a few minutes  of performing the test . 
HemeChip can also integrate with a mobile user interface (e.g.  IPhone, IPod), which 
shows the  test result quantitatively and objectively on the screen . HemeChip can be 
used  by [CONTACT_841814] a short (30 mi nute) training , eliminating the need for highly skilled 
personnel.   
2.AIMS
2.1  General objective  
The primary study objective is to validate the HemeCh ip technology as a novel, point -
of care (POC) platform for screening  SCD.  The results obtained using the HemeChip 
will be compared to High Performance Liquid Chromatography  (HPLC), and t he 
sensitivity and specificity of the HemeChip will be determined.  
2.2  Secondary objective  
i.To determine the acceptability of using the HemeChip  for POC screening  of
SCD during clinical assessments .
 Page 5 of 17 Version date: 1.4; 17 September 2018  3.LITERATURE REVIEW
Despi[INVESTIGATOR_841799] a global public health problem, SCD  remains a neglected 
health priority in many low- and middle -income countries. Ironically, the burden of 
haemoglobinopathies is projected to increase in the coming decades. By 2050, it is 
estimated that the proportion of sickle cell anaemia births in sub -Saharan Africa will 
be about 88% of the worldw ide total, compared to 79% in 2010. This increase will be 
largely as a result of population growth and public health transition .[ADDRESS_1169715] diagnostic testing for sickle cell disease in clude cellulose acetate or ci trate 
agar electrophoresis  (bench top electrophoresis) , IEF , high performance liquid 
chromatography (HPLC),  capi[INVESTIGATOR_841800] .11  
Bench top Hb electrophoresis : This is a laboratory method that can be done under 
alkaline or acidic conditions and with a variety of sieving materials such as gel or 
paper .[ADDRESS_1169716] high 
HbF levels, which may result in inaccurate identification of overlappi[INVESTIGATOR_841801].  
 Page 6 of 17 Version date: 1.4; 17 September 2018  Isoelectric Focusing  (IEF) : IEF exploits the fact that the net charge of a protein varies 
with the pH of the surrounding medium. Utilizing this variation, proteins are separated 
based on their isoelectric points (pI), which can be defined as the point at which a 
protein possesses zero net charge. The technique use s an applied electric field across 
a gel medium with a fixed pH gradient, each Hb type becomes immobilized once it 
reaches its pI. IEF exhibits higher resolution than Hb electrophoresis, thus it is capable 
of distinguishing between a larger number of Hb va riants . However, due to the larger 
number of bands that this higher resolution results in, IE F results are harder to 
interpret .12,13 IEF is also exp ensive and  results can be inaccur ate especially at low Hb  
concentrations. Despi[INVESTIGATOR_841802], IEF i s considered suitable for newborn 
screening since diagnosis is possible with very small sample volume or even an eluate 
from a dried blood spot .12 
High Performance Liquid Chromatography  (HPLC) : HPLC separates a fluid into its 
components based on size and c harge using cation exchange chromatography to  
identify the various Hb  types in a blood sample. Unique aspects of this test are full 
automation and accurate quantification of the Hb  levels. These machines are relatively 
expensive and are not readily available in developi[INVESTIGATOR_14696] .[ADDRESS_1169717].  
DNA Analysis : DNA -based assays can be used to detect the mutations in ùõΩ globin that 
produce abnormal Hb .[ADDRESS_1169718] often used for prenatal testing rather than 
postpartum .15  
HemeChip Technology : HemeChip  technology offers an original and innovative 
solution, leveraging a novel engineering approach, to point -of-care diagnosis of SC D. 
The basis of HemeChi p technology lies in Hb electrophoresis, in which Hb  types C, 
A2, S, F, and A0 have net negative charges  in an alkaline sol ution. Differences in Hb  
mobilities allow separation to occur within the sieving medium, cellulose acetate 
paper.  
 Page 7 of 17 Version date: 1.4; 17 September 2018  There is no POC device  for SCD or any other Hb  disorder screening on the market. 
Currently available tests require skilled technicians in central labs. In Africa , HPLC 
costs up to $[ADDRESS_1169719] year to six small businesses to deve lop affordable POC diagnostic 
technologies for SCD (Correlia Bio., Rockland Immun., Daktari Diag., Silver Lake 
Res., Halcyon Biom., and Qoolabs). The vast majority of these companies rely on 
lateral flow immunoassays, which embody specific antibodies. Unli ke the HemeChip 
technology, antibody based devices are specific to only a single disease, and would 
not work for different Hb  disorders. Furthermore, the performance and reliability of 
lateral flow devices quickly degrade under uncontrolled envir onmental conditions in 
resource -limited countries .[ADDRESS_1169720] methods (i.e., HPLC, bench -top 
electrophoresis) using 82 blood samples from 27 patient s at Unive rsity Hospi[INVESTIGATOR_600], 
Cleveland, [LOCATION_003] . HemeChip offers a $[ADDRESS_1169721] for SCD (and other Hb  
disorders), which takes 10 minutes to run. It is mobile and easy -to-use; it can be 
performed by [CONTACT_841814] a short (30 minute) training. The $2 HemeChip based 
newborn screening can be overlaid on existing successful (WHO, UNICEF data ) 
primary vaccination programs in sub -Saharan Africa, as a time -for-screening. Primary 
customers would be the front -line health care workers in government -established 
immunization programs  and pediatric clinics  in sub -Saharan Africa.  
4.METHODOLOGY
 Page 8 of 17 Version date: 1.4; 17 September 2018  4.1  Study design  
This is a single site, cross -sectional study.  
4.2 Study site  
Study participants  will be identified through the Community -Acquired Pneumonia and 
Invasive Bacteremia  Disease study (CAPI[CONTACT_225447]) currently enrolling at  three government 
hospi[INVESTIGATOR_841803] , Nigeria to include Amino Kano Teaching Hospi[INVESTIGATOR_307], Murtala 
Mohammed Specialist Hospi[INVESTIGATOR_841804].  
Aminu Kano Teaching Hospi[INVESTIGATOR_307] (AKTH) is one of the pi[INVESTIGATOR_841805]. 
The [ADDRESS_1169722] Hospi[INVESTIGATOR_307] (MMSH) and  Hasiya Bayero 
Children‚Äôs Hospi[INVESTIGATOR_841806], residents and 
students from AKTH rotate to gain pediatric experience.  
Murtala Mohammad Specialist Hospi[INVESTIGATOR_841807]. 
Established in [ADDRESS_1169723] Africa. It is 
located in the central city of Kano State and as such, caters for a majority of the 
estimated 10 million people in the State. The hospi[INVESTIGATOR_56756] a staff strength of 1,917 out 
of which, there are about 97 medica l doctors and 415 nursing staff . The outpatient 
clinics cater for an average of 30,000 patients monthly.  
4.3 Subjects/study population  
Subjects  eligible for this study include  children age  6 weeks  to 60 months   enrolled  in 
CAPI[INVESTIGATOR_841808], Nigeria.  
 Page 9 of 17 Version date: 1.4; 17 September 2018  Inclusion/Exclusion criteria  
Inclusion criteria:  
Age 6 weeks to 60  months with one of the  following true : 
1.fever or hypothermia (Temp ‚â•38
 C or ‚â§36
 C)  Plus one of the following
(prostration, excessive crying, poor feeding, altered consciousness, convulsion,
difficulty breathing, profuse vomiting, diarrhea)
2.Rapid breathing (0 -2months>60 breaths/min, 3 -12months >50 breaths/min, 13 -
59 months > 40 breaths /min)
AND  
3.Provision of signed and dated written informed consent by [CONTACT_841815] : 
1. Parent of child chooses to opt out of the study after initial consent .
2. Blood transfusion  within 3 months of study enrollment.
3. Presence of  condition or abnormality that in the opi[INVESTIGATOR_841809].
4.4 Sample size estimate  
Sample size is based  on the known prevalence of SCD in Nigeria  (SCD prevalence 
of 2.39% and a carrier rate of about 23% )19, using the following formula and a 9 5% 
confidence interval .17 
1.Specify clinically acceptable values for the width of 95% confidence interval
(CI), sensitivity (SN), specificity (SP), and the disease prevalence (P).
2.Calculate the  number of patients with disease, defined as the sum of true
positive cases (TP) and false negative cases (FN) using:
22
2 /) 1 (
WSN SNZ FN TPÔÄ≠ÔÄΩ ÔÄ´ÔÅ°
3.Calculate the sample size required to obtain the desired sensitivity as:
PFN TPNÔÄ´ÔÄΩ1
4.Calculate the number of patients without disease, defined as the sum of true
negative cases (TN) and false positive cases (FP) using:
 Page 10 of 17 Version date: 1.4; 17 September 2018  
22
2 /) 1 (
WSP SPZ FP TNÔÄ≠ÔÄΩ ÔÄ´ÔÅ°5.Calculate the sample size required to obtain the desired specificity as:
PFP TNNÔÄ´ÔÄΩ2
Where Z Œ±/2 is a statistical constant having a value of 1.96 for 95% CI.  
6.Select the required sample size as the greater of N1 and N2.
The calculations made for the HemeChip test sample size  are summarized in  
Table 1 below:  
Prevalence estimate    P 
Width of the 95% CI: 10%   W 
Sensitivity expected: 98%    SN 
Specificity expected: 98%    SP 
Statistical constant, 1.96 for 95% CI   Zalpha  
Number with disease, True Positive + False Negative   TP+FN  
Sample size required for sensitivity   N1 
Number without disease, False Positive + True Negative   FP+TN  
Sample size required for specificity     N2 0.024  
0.10 
0.97 
0.97 
1.96 
11 
468 
11 
11 
FINAL SAMPLE SIZE (greater of N1 and N2)  468 
Total maximum enrollment of 5,000 patients, age 6 weeks to 60 months
identified through CAPI[CONTACT_225447].  
 Page 11 of 17 Version date: 1.4; 17 September 2018  Procedure  
The CAPI[INVESTIGATOR_841810]/caregiver 
is willing to participate . If yes, signed informed consent will be obtained and the 
subject  assign ed a unique identification number  through CAPI[CONTACT_225447] . The clinical 
research assistant  (CRA) assigned to the study will complete a questionnaire  
including demographic data and family information, and perform a heel or finger 
prick to obtain a blood sample for HemeChip and HPLC  (page 12 ).  
HemeChip Test  
a.Finger -stick or  heel-stick blood sample  (20 ¬µL) is mixed with deionized
water  for red blood cell  lysis and the mixture allowed to set for [ADDRESS_1169724] 
a.All blood samples c ollected via heel or finger prick on dot -blot paper will be
shipped  to the IFAIN  lab in Abuja on a monthly basis.
 Page 12 of 17 Version date: 1.4; [ADDRESS_1169725]‚Äôs visit into the protocol -specific electronic Case Report 
Form (eCRF) . All data collected duri ng the course of this study will  be reviewed and 
verified for completenes s and accuracy by [CONTACT_978] .  
The data will be entered into a va lidated database , which will allow safe and  secure 
storage . After data have been entered into the study database, a system of 
computerized data validation checks will be implemented and applied to the database 
on a regular basis. Any changes to the study d atabase will be documented.  
4.5  Statistical analysis  
Data will  be analyzed and reported based on established methods in the literature.18 
Statistical significance will be set at 95% confidence level for all tests (p<0.05). 
Receiver -operating curves will be utilized to assess sensitivity and specificity of 
 Page 13 of 17 Version date: 1.4; [ADDRESS_1169726]. Sensitivity will be calculated 
as # true positives / (# true positives + # false negatives) and specificity will be 
calculated as # true negatives / (# true negatives + # false positives). Positive 
predictive value (PPV) will be calculated as # true positives / (# true positives + # false 
positives) and negative predictive value (NPV) will be calculated as # true negatives / 
(# true negatives + # f alse negatives).  
[ADDRESS_1169727] their origin 
in the Declaration of Helsinki and are consistent with the International Conference on 
Harmonization  (ICH)/Good Clinical Practice (GCP).   
Informed consent  
All study pa rticipants must have a legal representative that is in competent mental 
condition to provide written, informed consent on behalf of the study subject before 
entering the study. A copy of the signed informed consent form will be given to the 
parent or legal  guardian. ‚Ä®Each subject , parent or legal guardian will be notified t hat 
they are free to withdraw  from the study at any time. ‚Ä® 
6.[ADDRESS_1169728]  
There will be no research activity performed or data collection at UNMC. All research 
activity and data collecti on will be performed at the Nigeria site. The CWRU  team  will 
take responsibility for data collection, storage, submitting continuing reviews and 
 Page 14 of 17 Version date: 1.4; 17 September 2018  amendments for the study. CWRU  team  will also give the approved documents to 
UNMC  in a timely manner  and make s ure to keep track of everything that occurs at that 
site.  
University of Nebraska Medical Center (UNMC)  has developed several microbiology 
diagnostic laboratories for invasive bacterial infections in Nigeria children. UNMC 
supports the International Foundation Against Infectious Disease (IFAIN),a registered 
non-profit in Nigeria, which manages local research  activities. The Co -I from 
UNMC,  (Stephen Obaro)  is founding member and Trustee of IFAIN  and the PI [INVESTIGATOR_841811].  Some of the 
services IFAIN provides include microbiology and molecular diagnostic services, such 
as sickle cell disease screening through HPLC. UNMC also has a strong network with 
multiple researchers across Africa who work with hemoglobinopathies and vaccine 
preventable infections. UNMC provides essential expertise and support to fulfi ll the 
activities for our proposal.   
6.6 Safety  
The study poses minimal risk to participants. There will be the minor discomfort of a 
heel (or finger) prick . Bruising at the site of skin puncture may occur. For 
parents/caregivers, there is a small, time inconvenience  for administration of the st udy 
questionnaire.  
Timeline/Work schedule  
Timeline: 
ÔÇ∑IRB approval: 2 months ( FEB/MAR  2017)
ÔÇ∑Recruitment and training of study staff: 1 month ( MAR 2017 )
 Page 15 of 17 Version date: 1.4; 17 September 2018  ÔÇ∑Recruitment : 3 months (APR 2017  to JULY  2017)
ÔÇ∑Data entry, cleaning and analysis: APR 2017 to AUG 2017
ÔÇ∑Write up and dissemination: AUG [ADDRESS_1169729] 2017
International Collaborators: 
Umut A. Gurkan, PhD  
Assistant [CONTACT_841816] and Microfabrication Laboratory  
Mechanical and Aerospace Engineering Department  
Biomedical Engineering Department  
Case Western Reserve University  (CWRU)  
Office: Glennan 616B,  [ADDRESS_1169730]., Cleveland, OH [ZIP_CODE]  
 Phone: +1 (216) 368 -6447  
 Fax: +1 (216) 368 -3007  
 Email: [EMAIL_15946] ; Web: http://www.case -bml.net  
Stephen K. Obaro, M.D., Ph.D.  
Professor, Division of Pediatric Infectious Diseases  
University of Nebraska Medical Center  
982162 Nebraska Medical Center  
Omaha, Nebraska [ZIP_CODE] -2162  
[EMAIL_15947]   
REFERENCES
1.Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood
Cancer. 2012;59(2):386 -390.
2.Mulumba LL, Wilson L. "Sickle cell disease among children in Africa: An
integrative literature review and global recommendations". International Journal
of Africa Nursing Sciences, 3: p. 56 -64, 2015.
 Page 16 of 17 Version date: 1.4; 17 September 2018  3.Manwani D , Frenette P. Vaso -occlusion in sickle cell disease: pathophysiology
and novel targeted therapi[INVESTIGATOR_014]. Blood. 2013;122( 24):3892 -3898.
4.Jain D , Lothe A , Colah R . Sickle cell disease: current c hallenges. J Hem atol
Thrombo Dis . 2015; 3:224. doi:10.4172/2329 -8790.1000224 .
5.Pi[CONTACT_139020] F, Hay S, Gupta S, We atherall D, Williams T. Global burden of sickle c ell
anaemia  in children under five, 2010 ‚Äì2050: modelling based on demographics,
excess mortality, and i nterventions. PLoS Med. 2013;10(7):e1001484.
6.Odievre MH, Verger E, Silva -Pi[INVESTIGATOR_545443], Elion J. Pathophysiological insights  in
sickle cell disease. Indian J Med Res. 2011;134:532 -537.
7.Kanter J , Kruse -Jarres R. Management of sickle cell disease from childhood
through adulthood. Blood Rev . 2013;27(6):[ADDRESS_1169731] D , Earles A, Kleman K , Lubin B . Newbor n screening for sickle
cell disease: effect on mortality . Pediatrics.  1988 ;81(6):749 -55.
9.Frempong T, Pearson HA. Newborn screening coupled with comprehensive
follow -up reduced early mortality of sickle cell disease in Connecticut.  Conn Med.
2007;71(1):9 -12.
10.Odame I. Developi[INVESTIGATOR_007] a global agenda for sickle cell d isease. Am J Prev Med .
2010;38(4):S571 -S575.  
11. Wethers DL. Sickle cell disease in childhood: Part II. Diagnosis and treatment of
major complications and recent advances in treatment. Am Fam
Physician.2000; 62(5):1013 -1020.
12.Bain BJ.  Haemoglobinopathy Diagnosis. 2nd ed. Malden, MA, [LOCATION_003]: Blackwell;
2006.  
13.Bain BJ, Wild B, Stephens A, Phelan L. Variant haemoglobins: a guide to
identification. Oxford, [LOCATION_006]: Wiley -Blackwell; 2011. 260 p.  
14.Clark BE, Thein SL. Molecular diagnosis of haemoglobin di sorders. Clinical Lab
Haematol . 2004;26(3):159 -176. 
15.Ashley -Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle
 Page 17 of 17 Version date: 1.4; 17 September 2018  cell d isease: a HuGE review. Am J Epi[INVESTIGATOR_5541] . 2000;151(9 ):[ADDRESS_1169732], Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J , et al.
The heat stability of p lasmodium lactate dehydrogenase -based and histidine -rich 
protein 2 -based malaria rapid diagn ostic tests. Trans Roy Soc Trop Medicine 
Hyg. 2007;101(4):331 -337. 
17. Buderer NM . Statistical Met hodology: I. Incorporating the prevalence of disease
into the sample size calculation for sensitivity and s pecificity. Acad Emerg Med .
1996;3(9):895 -900.
18. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thom as R. Understanding and
using sensitivity, specificity and p redictive values. Indian J Ophthalmol .
2008;56(1):45 -50.
19. Ademola Samson Adewoyin, ‚ÄúManagement of Sickle Cell Disease: A Review for
Physician Education in Nigeria (Sub -Saharan Africa),‚Äù Anemia, vo l. 2015, Article
ID 791498, 21 pages, 2015